Therapeutic PEG solution concentrate

• US 20060029570A1
• Filed: 11/17/2004
• Published: 02/09/2006
• Est. Priority Date: 11/17/2003
• Status: Abandoned Application

• Current Assignee: Braintree Laboratories Incorporated (Sebela International Limited)
• Original Assignee: Braintree Laboratories Incorporated (Sebela International Limited)
• Inventors: Aronson, Bruce Howard, Gay, Stanley Edward
• Application Number:
  US10/990,796
• Publication Number:
  US 20060029570A1
• Time in Patent Office: Days
• US Class Current: 424/78.380
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/765 Polymers containing oxygen
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61K 33/06 Aluminium, calcium or magnesium; Compounds thereof , e.g. clay
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/10 Laxatives

Abstract

The present invention provides a polyethylene glycol liquid concentrate for treatment of constipation or for gastrointestinal lavage that is chemically stable and resistant to microbial contamination.

Claims

1. A composition comprising a shelf stable and microbially-resistant therapeutic solution comprising an aqueous polyethylene glycol concentrate.

2. The composition of claim 1, wherein the polyethylene glycol has an average molecular weight greater than about 1,000 Daltons to about 20,000 Daltons.

3. The composition of claim 2, wherein the polyethylene glycol has an average molecular weight ranging from about 1,500 Daltons to about 20,000 Daltons.

4. The composition of claim 3, wherein the polyethylene glycol has an average molecular weight ranging from about 3,000 Daltons to about 8,000 Daltons.

5. The composition of claim 4, wherein the polyethylene glycol is PEG 3350.

6. The composition of claim 1, wherein the solution comprises from about 0.1 g to about 0.8 g polyethylene glycol per ml of solution.

7. The composition of claim 1, wherein the solution comprises about 0.6 g/ml polyethylene glycol per dose.

8. The composition of claim 1, wherein the solution comprises from about 5 g to about 500 g polyethylene glycol per dose.

9. The composition of claim 1, further comprising electrolytes.

10. The composition of claim 1, which is provided in a form that is liquid, frozen, and/or incorporated into foodstuffs.

11. The composition of claim 1, further comprising a stimulant laxative.

12. The composition of claim 1, further comprising a sweetener.

13. The composition of claim 1, further comprising flavorings, stabilizers, and/or preservatives.

14. The composition of claim 1, further comprising fiber.

15. A method of treating constipation in a patient in need thereof, the method comprising administering to the patient the composition of claim 1.

16. A method of treating constipation in a patient in need thereof, the method comprising administering to the patient the composition of claim 5.

17. A method of treating constipation in a patient in need thereof, the method comprising:

a) diluting the composition of claim 1;

and

b) administering the diluted composition to the patient.

18. A method for effecting gastrointestinal lavage in a patient in need thereof, the method comprising administering to the patient the composition of claim 1.

19. A method for effecting gastrointestinal lavage in a patient in need thereof, the method comprising administering to the patient the composition of claim 5.

20. A method for effecting gastrointestinal lavage in a patient in need thereof, the method comprising:

a) diluting the composition of claim 1;

and

b) administering the diluted composition to the patient.